NCT06155955

Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A

Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Chulalongkorn University · Academic / Other
• Sex: Male
• Age: 3 Years – 30 Years
• Healthy volunteers: Accepted

Summary

* To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration * To study pharmacokinetic, side effect of low dose Emicizumab

Detailed description

* To compare outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration using ABR, AJBR and HJHS, HaemoQoL * To study pharmacokinetic, side effect and effectiveness of low dose Emicizumab

Conditions

• Severe Hemophilia A Without Inhibitor
• Joint Bleed

Interventions

Type	Name	Description
DRUG	"Emicizumab", "HEMLIBRA®"	low dose

Timeline

• Start date: 2023-06-22
• Primary completion: 2024-03-21
• Completion: 2024-06-21
• First posted: 2023-12-05
• Last updated: 2024-03-05

Locations

1 site across 1 country: Thailand